142 related articles for article (PubMed ID: 27072250)
1. Effect of gemcitabine on the uptake of (18)F-fluorodeoxyglucose and (18)F-fluorothymidine in lung adenocarcinoma A549 cells and the animal tumor model.
Zhang B; Deng SM; Guo LC; Dong JJ; Zhu YB; Gao Y; Wang ZX; Cho WC
J Cancer Res Ther; 2016; 12(1):271-6. PubMed ID: 27072250
[TBL] [Abstract][Full Text] [Related]
2. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
3. Early Prediction of Radiotherapeutic Efficacy in a Mouse Model of Non-Small Cell Lung Carcinoma Using
Otani T; Ikushima H; Bando Y; Yamashita M; Kuwahara K; Otsuka H; Kondo K; Miyoshi H
J Med Invest; 2023; 70(3.4):361-368. PubMed ID: 37940520
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
Schelhaas S; Held A; Wachsmuth L; Hermann S; Honess DJ; Heinzmann K; Smith DM; Griffiths JR; Faber C; Jacobs AH
Cancer Res; 2016 Dec; 76(24):7096-7105. PubMed ID: 27784748
[TBL] [Abstract][Full Text] [Related]
5. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
Schelhaas S; Wachsmuth L; Viel T; Honess DJ; Heinzmann K; Smith DM; Hermann S; Wagner S; Kuhlmann MT; Müller-Tidow C; Kopka K; Schober O; Schäfers M; Schneider R; Aboagye EO; Griffiths J; Faber C; Jacobs AH
J Nucl Med; 2014 Jun; 55(6):983-8. PubMed ID: 24777288
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
[TBL] [Abstract][Full Text] [Related]
7. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
[TBL] [Abstract][Full Text] [Related]
8. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
[TBL] [Abstract][Full Text] [Related]
9. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer.
Huang T; Civelek AC; Li J; Jiang H; Ng CK; Postel GC; Shen B; Li XF
J Nucl Med; 2012 Aug; 53(8):1262-8. PubMed ID: 22717978
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.
Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL
Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224
[TBL] [Abstract][Full Text] [Related]
12. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
[TBL] [Abstract][Full Text] [Related]
13. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
14. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
[TBL] [Abstract][Full Text] [Related]
15. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
[TBL] [Abstract][Full Text] [Related]
16. Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis.
Shen G; Ma H; Pang F; Ren P; Kuang A
Acta Radiol; 2018 Feb; 59(2):188-195. PubMed ID: 28475024
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Kobe C; Scheffler M; Holstein A; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Dietlein M; Wolf J; Kahraman D
Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1117-27. PubMed ID: 22526960
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Scheffler M; Zander T; Nogova L; Kobe C; Kahraman D; Dietlein M; Papachristou I; Heukamp L; Büttner R; Boellaard R; Lammertsma AA; Querings S; Stoelben E; Engel-Riedel W; Neumaier B; Wolf J
PLoS One; 2013; 8(1):e53081. PubMed ID: 23308140
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
20. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
